This site is intended for health professionals only

Targeted Anticancer Therapies 2013

teaser

The provisional meeting schedule is online now, including keynote and session themes:
Programme:
  • New immune checkpoints as drug targets
  • Phase 1 studies, completed or in progress
  • Whole-genome sequencing in early-phase development
  • Metabolic targets
  • Immunoconjugates for cancer therapy
  • Emerging new drugs and targets in hemato-oncology
  • Drugs targeting the RAS/RAF/MEK pathway
  • Preclinical models in drug discovery and development
A new element is the special biotech event, which will feature biotechs’ innovations in oncology. It will provide delegates a great view of the innovations (small) biotech companies are bringing to cancer patient management It will offer excellent business-to-business networking opportunities between biotech companies and academic investigators as well as biotech and pharma representatives.
www.tatcongress.org/progr-tat13.html





Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x